Atherogenic index of plasma as a stroke-subtype–independent predictor of acute cognitive dysfunction in ischemic stroke: A cross-sectional analytic study
Keywords:
Atherogenic Index of Plasma, Cognitive function, Ischemic Stroke subtype, Ischemic StrokeAbstract
Background and aim: Cognitive impairment is a common complication in the acute phase of ischaemic stroke (IS). The Atherogenic Index of Plasma (AIP) has been proposed as a potential marker of vascular risk; however, its relationship with cognitive function across different stroke subtypes remains unclear. This study aimed to evaluate the association between AIP and cognitive performance, with consideration of IS subtypes, using the Montreal Cognitive Assessment Indonesian Version (MoCA-Ina). Methods: A cross-sectional analytic study was conducted at Dr. Wahidin Sudirohusodo General Hospital, Makassar, from July to December 2025. Patients aged ≥40 years with first-ever acute ischaemic stroke (onset 24 hours–7 days) and preserved consciousness were included. Exclusion criteria comprised recurrent stroke, transient ischaemic attack, aphasia, pre-existing dementia, systemic or psychiatric conditions affecting cognition or lipid metabolism, and prior lipid-lowering therapy. AIP was calculated as log₁₀ (triglyceride/HDL-C). Cognitive function was assessed using MoCA-Ina, and stroke subtype was classified as lacunar or non-lacunar. Statistical analyses included Spearman correlation, Mann–Whitney, and independent t-tests. Results: Most patients showed cognitive impairment (74%; median MoCA-Ina 23.00) and high-risk AIP levels (65%; mean 0.285). AIP demonstrated a significant negative correlation with total MoCA-Ina score (r = -0.342; p = 0.001). Non-lacunar stroke patients showed lower cognitive scores compared with lacunar stroke (mean 19.02 vs 21.90; p = 0.028). In contrast, AIP values did not differ between subtypes (p = 0.991). Conclusions: Higher AIP is associated with worse cognitive performance in the acute phase of ischaemic stroke. This finding suggests that atherogenic dyslipidaemia may contribute to early cognitive decline irrespective of stroke subtype.
References
1. Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018;2018:3238165. doi: 10.1155/2018/3238165.
2. Dichgans M, Leys D. Vascular cognitive impairment. Circ Res. 2017;120(3):573-91. doi: 10.1161/CIRCRESAHA.116.308426.
3. Nys GM, van Zandvoort MJ, de Kort PL, et al. Cognitive disorders in acute stroke: prevalence and clinical determinants. Cerebrovasc Dis. 2007;23(5-6):408-16. doi: 10.1159/000101464.
4. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006-18. doi: 10.1016/S1474-4422(09)70236-4.
5. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18. doi: 10.1097/WAD.0000000000000034.
6. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. Stroke. 1993;24(1):35-41. doi: 10.1161/01.str.24.1.35.
7. Rundek T, Tolea M, Ariko T, et al. Vascular cognitive impairment (VCI). Neurotherapeutics. 2022;19(1):68-88. doi: 10.1007/s13311-021-01170-y.
8. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-38. doi: 10.1016/S1474-4422(13)70124-8.
9. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701. doi: 10.1016/S1474-4422(10)70104-6.
10. Markus HS, de Leeuw FE. Cerebral small vessel disease: recent advances and future directions. Int J Stroke. 2023;18(1):4-14. doi: 10.1177/17474930221144911.
11. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022;23(6):3346. doi: 10.3390/ijms23063346.
12. Anbar R, Jones S, Chaturvedi N, et al. Associations of carotid atherosclerosis with cognitive function and brain health: findings from a UK tri-ethnic cohort study (Southall and Brent revisited). Atheroscler Plus. 2024;55:39-46. doi: 10.1016/j.athplu.2024.01.002.
13. Eslami MH, Sedokani A, Panahi N, et al. The association between atherogenic index of plasma and cognitive impairment among older adults in Southern Iran: findings from the Bushehr elderly health program. BMC Geriatr. 2025;25(1):614. doi: 10.1186/s12877-025-06224-w.
14. Liu H, Liu K, Pei L, et al. Atherogenic index of plasma predicts outcomes in acute ischemic stroke. Front Neurol. 2021;12:741754. doi: 10.3389/fneur.2021.741754.
15. Zheng H, Wu K, Wu W, et al. Relationship between the cumulative exposure to atherogenic index of plasma and ischemic stroke: a retrospective cohort study. Cardiovasc Diabetol. 2023;22(1):313. doi: 10.1186/s12933-023-02044-7.
16. Zhou J, Han H, Bai W. Association between atherogenic index of plasma and cognitive impairment in middle-aged and older adults: results from CHARLS. Front Aging Neurosci. 2025;17:1506973. doi: 10.3389/fnagi.2025.1506973.
17. Gao Y, Li D, Lin J, et al. Cerebral small vessel disease: pathological mechanisms and potential therapeutic targets. Front Aging Neurosci. 2022;14:961661. doi: 10.3389/fnagi.2022.961661.
18. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-96. doi: 10.1016/S1474-4422(19)30079-1.
19. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844-66. doi: 10.1016/j.neuron.2013.10.008.
20. Dong Y, Lee WY, Basri NA, et al. The Montreal cognitive assessment is superior to the Mini-Mental State Examination in detecting patients at higher risk of dementia. Int Psychogeriatr. 2012;24(11):1749-55. doi: 10.1017/S1041610212001068.
21. Wang Q, Jiang G, Yan L, et al. Association of atherogenic index of plasma with early neurological deterioration in patients with acute ischemic stroke. Clin Neurol Neurosurg. 2023;234:108014. doi: 10.1016/j.clineuro.2023.108014.
22. Gordon DL, Bendixen BH, Adams HP Jr, et al. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. Neurology. 1993;43(5):1021-7. doi: 10.1212/wnl.43.5.1021.
23. Akivis Y, Alkaissi H, McFarlane SI, et al. The role of triglycerides in atherosclerosis: recent pathophysiologic insights and therapeutic implications. Curr Cardiol Rev. 2024;20(2):39-49. doi: 10.2174/011573403X272750240109052319.
24. O'Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698-706. doi: 10.1016/S0140-6736(15)00463-8.
25. Zhao L, Biesbroek JM, Shi L, et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study. J Cereb Blood Flow Metab. 2018;38(8):1299-1311. doi: 10.1177/0271678X17728162.
26. Cannistraro RJ, Badi M, Eidelman BH, et al. CNS small vessel disease: a clinical review. Neurology. 2019;92(24):1146-56. doi: 10.1212/WNL.0000000000007654.
27. Padro T, Muñoz-Garcia N, Badimon L. The role of triglycerides in the origin and progression of atherosclerosis. Clin Investig Arterioscler. 2021;33 Suppl 2:20-28. doi: 10.1016/j.arteri.2021.02.007.
28. Blagov AV, Churov AV, Golovyuk AL, et al. The role of metabolic disorders in the development of atherosclerosis. Cell Mol Biol (Noisy-le-grand). 2024;70(9):148-55. doi: 10.14715/cmb/2024.70.9.21.
29. Frazier DT, Seider T, Bettcher BM, et al. The role of carotid intima-media thickness in predicting longitudinal cognitive function in an older adult cohort. Cerebrovasc Dis. 2014;38(6):441-7. doi: 10.1159/000366469.
30. Nam KW, Kwon HM, Park JH, Kwon H. The atherogenic index of plasma is associated with cerebral small vessel disease: a cross-sectional study. J Lipid Atheroscler. 2022;11(3):262-71. doi: 10.12997/jla.2022.11.3.262.
31. Inoue Y, Shue F, Bu G, et al. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease. Mol Neurodegener. 2023;18(1):46. doi: 10.1186/s13024-023-00640-5.
32. Onkenhout L, Appelmans N, Kappelle LJ, et al. Cerebral perfusion and the burden of small vessel disease in patients referred to a memory clinic. Cerebrovasc Dis. 2020;49(5):481-6. doi: 10.1159/000510969.
33. Cuadrado-Godia E, Dwivedi P, Sharma S, et al. Cerebral small vessel disease: a review focusing on pathophysiology, biomarkers, and machine learning strategies. J Stroke. 2018;20(3):302-20. doi: 10.5853/jos.2017.02922.
34. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2(8):80. doi: 10.3978/j.issn.2305-5839.2014.08.05.
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
